Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies
- PMID: 30442303
- DOI: 10.1016/j.jacc.2018.09.024
Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies
Comment on
-
Global Prospective Safety Analysis of Rivaroxaban.J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058. J Am Coll Cardiol. 2018. PMID: 29976287
-
Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies.J Am Coll Cardiol. 2018 Nov 13;72(20):2545-2546. doi: 10.1016/j.jacc.2018.07.104. J Am Coll Cardiol. 2018. PMID: 30442302 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical